EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Asa P Y Lau, Lilian G Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M Saleeb, Heyu Ni, Kelsie L Thu iD

Molecular Oncology · 2026-08 · 20 (8) · 1963-1985

DOI: 10.1002/1878-0261.70237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 20.04.2026. Verfasst von Asa P Y Lau und 8 weiteren Autor:innen. Beteiligte Einrichtung: Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, CD47 Antigen, Epithelial-Mesenchymal Transition, Lung Neoplasms. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Unity Health Toronto, JP Bickell Foundation, Canada Research Chairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD47 is best known for its role in tumor immune evasion; however, studies in diverse cell models indicate that it also has cell autonomous, tumor‐promoting functions which are cell type‐ and context‐specific. Motivated by the prognostic and therapeutic significance of CD47 and the limited knowledge regarding its roles beyond immune evasion in non‐small cell lung cancer (NSCLC), we sought to define the cellular and molecular processes driven by intrinsic CD47 signaling in NSCLC. Transcriptome profiling of CD47 wild‐type and knockout NSCLC cells implicated its regulation of genes enriched for signatures of mitogen‐activated protein kinase (MAPK) signaling and epithelial‐to‐mesenchymal transition (EMT). A significant positive association between CD47 and MAPK/EMT expression signatures was also evident in large cohorts of NSCLC cell lines and tumor tissues. Functional studies indicated that CD47 does not regulate cell proliferation in NSCLC cells like it does in other cancer types. Instead, CD47 regulates cell adhesion and migration through an ERK and EMT axis, validating our transcriptomic findings. Moreover, CD47 loss‐of‐function significantly diminished the ability of NSCLC cells to metastasize in vivo , demonstrating the physiological relevance of cell‐intrinsic CD47 signaling in lung cancer cells. Our data reveal a novel role for CD47 in relaying signals through ERK to promote EMT expression programs and prometastatic phenotypes in NSCLC. Although additional mechanistic studies are needed to further decipher the CD47‐ERK‐EMT signaling pathway, our findings reinforce the therapeutic potential of CD47, rationalizing further research to develop CD47 blockade as a multimodal therapy for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCD47 AntigenEpithelial-Mesenchymal TransitionLung NeoplasmsMitogen-Activated Protein KinasesHumansCell Line, TumorAnimalsPhenotypeGene Expression Regulation, NeoplasticNeoplasm MetastasisCell MovementCell ProliferationCell AdhesionMAP Kinase Signaling System

Stichwörter der Autor:innen

CD47EMTMAPK signalingNSCLCRNA sequencing

Substanzen

CD47 AntigenMitogen-Activated Protein KinasesCD47 protein, human

Autor:innen und Institutionen

  • Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada.
  • Department of Physiology, University of Toronto, Canada.
  • Department of Medicine, University of Toronto, Canada.
  • Canadian Blood Services Centre for Innovation, Toronto, Canada.

ORCID-Profile: Kelsie L Thu

Förderung

  • Unity Health Toronto
  • JP Bickell Foundation
  • Canada Research Chairs
  • Cancer Research Society
  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Lau, A. P. Y., Zhai, L. G., Hoshi, R., Rousseau, Z., Zakhary, A., Wu, Y. F., Saleeb, R. M., Ni, H., & Thu, K. L. (2026). CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer. Molecular Oncology, 20(8), 1963-1985. https://doi.org/10.1002/1878-0261.70237

Vancouver

Lau APY, Zhai LG, Hoshi R, Rousseau Z, Zakhary A, Wu YF, et al. CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer. Molecular Oncology. 2026;20(8):1963-1985. doi:10.1002/1878-0261.70237

BibTeX
@article{Lau2026,
  author = {Lau, Asa P Y and Zhai, Lilian G and Hoshi, Ryunosuke and Rousseau, Zackary and Zakhary, Abraam and Wu, Yin Fang and Saleeb, Rola M and Ni, Heyu and Thu, Kelsie L},
  title = {CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {8},
  pages = {1963--1985},
  doi = {10.1002/1878-0261.70237}
}
Kostenlos starten →